Back to top
more

Mallinckrodt public limited company (MNK)

(Delayed Data from NYSE)

$16.14 USD

16.14
1,972,598

+0.44 (2.80%)

Updated May 3, 2019 04:02 PM ET

After-Market: $16.14 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Avenue Therapeutics' Pain Drug Gets Complete Response Letter

Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.

Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall

Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.

Why Is Mallinckrodt (MNK) Down 3.9% Since Last Earnings Report?

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Implied Volatility Surging for Mallinckrodt (MNK) Stock Options

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Kinjel Shah headshot

Opioid Crisis Deepens as Teva, Allergan Face Fraud Charges

The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products

Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates

Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.

Mallinckrodt (MNK) Beats Q2 Earnings and Revenue Estimates

Mallinckrodt (MNK) delivered earnings and revenue surprises of 51.20% and 12.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Earnings Preview: Mallinckrodt (MNK) Q2 Earnings Expected to Decline

Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Ranked Growth Stocks to Buy for July 24th

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 24th

Indrajit Bandyopadhyay headshot

Uncertainty Looms Large Over Generic Drug Industry Players

Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.

Are Options Traders Betting on a Big Move in Cameco Mallinckrodt (MNK) Stock?

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

FDA Advisory Committee Recommends Mallinckrodt's Trelipressin

The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.

FDA Advisory Committee to Review Mallinckrodt'sTerlipressin

Mallinckrodt (MNK) announces that the Cardiovascular and Renal Drugs Advisory Committee of the FDA will hold a virtual meeting to review data on terlipressin.

Heron's Pain Management Drug Gets Complete Response Letter

Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.

Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue

Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns

Why Is Mallinckrodt (MNK) Down 5.8% Since Last Earnings Report?

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Implied Volatility Surging for Mallinckrodt (MNK) Stock Options

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed

Bausch (BHC) misses on earnings and sales in the first quarter and lowers guidance due to the coronavirus pandemic.

Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling

Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic

Mallinckrodt (MNK) Q1 Earnings Beat Estimates, Sales Miss

Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.

Mallinckrodt (MNK) Q1 Earnings Surpass Estimates

Mallinckrodt (MNK) delivered earnings and revenue surprises of 16.31% and -2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Mallinckrodt (MNK) to Report a Decline in Earnings: What to Look Out for

Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Mallinckrodt (MNK) is Poised to Beat Earnings Estimates Again

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue

Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.